Investigational drug · Phase 2
Allocetra
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Knee Osteoarthritis, Osteoarthritis, Knee.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
14
Any phase or sponsor naming "Allocetra"
First trial start
2024
Jan 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Allocetra", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Primary Knee Osteoarthritis
- Osteoarthritis, Knee
Approved drugs for the same conditions: Osteoarthritis
Largest trials
Live from ClinicalTrials.gov: studies naming "Allocetra" as an intervention, largest first.
- Intra-Articular Allocetra in Patients With Primary Knee OsteoarthritisPivotal-lookingRecruiting
Enlivex Therapeutics Ltd.Industry
NCT07580716 · 182 participants (planned) · Start May 1, 2026 · Primary completion Feb 2027
Drug: Allocetra · For: Primary Knee Osteoarthritis
Sites: Longwood, Florida; Miami, Florida; New Orleans, Louisiana · 17 sites in all
- A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis PatientsPivotal-lookingCompleted
Enlivex Therapeutics Ltd.Industry
NCT04612413 · 148 participants · Start Nov 30, 2020 · Primary completion Jan 12, 2024
Drug: Allocetra-OTS · For: Sepsis; Community-acquired Pneumonia; Urinary Tract Infections and 3 more
Sites: Brussels, Belgium; Charleroi, Belgium; Genk, Belgium · 31 sites in all
- Study of Intra-articular Allocetra in Knee OsteoarthritisPivotal-lookingCompleted
Enlivex Therapeutics Ltd.Industry
NCT06233474 · 134 participants · Start Jan 26, 2024 · Primary completion Mar 15, 2026
Drug: Allocetra · For: Osteoarthritis, Knee
Sites: Gandrup, Denmark; Herlev, Denmark; Vejle, Denmark · 12 sites in all
- Intra-articular Allocetra in Osteoarthritis of the 1st Carpo-metacarpal JointActive, not recruiting
Kaplan Medical CenterAcademic, hospital or other
NCT06459063 · 46 participants (planned) · Start Jun 10, 2024 · Primary completion Sep 2026
Drug: Allocetra - Safety run-in phase; Allocetra - Randomization phase · For: Osteoarthritis Thumb
Sites: Rehovot, Israel
- Allocetra-OTS in COVID-19, Phase IIStatus unknown
Hadassah Medical OrganizationAcademic, hospital or other
NCT04590053 · 24 participants (planned) · Start Oct 20, 2020 · Primary completion Feb 2021
Drug: Allocetra-OTS · For: Covid19
Sites: Ashkelon, Israel; Jerusalem, Israel; Tel Aviv, Israel
- Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of SafetyActive, not recruiting
Amir OronAcademic, hospital or other
NCT06208241 · 18 participants (planned) · Start Jul 12, 2023 · Primary completion Sep 25, 2026
Drug: Allocetra-OTS · For: Knee Osteoarthritis
Sites: Rehovot, Israel
Enlivex Therapeutics Ltd.Industry
NCT04659304 · 18 participants (planned) · Start Dec 2021 · Primary completion Sep 2022
Drug: Allocetra-OTS · For: Covid19
Enlivex Therapeutics RDO Ltd.Industry
NCT05581719 · 14 participants · Start Nov 15, 2022 · Primary completion Apr 15, 2024
Drug: Allocetra-OTS; Nivolumab and 1 more · For: Solid Tumor; Peritoneal Metastases; Peritoneal Cancer
Sites: Haifa, Israel; Jerusalem, Israel; Ramat Gan, Israel · 6 sites in all
Enlivex Therapeutics Ltd.Industry
NCT04922957 · 12 participants · Start Sep 1, 2021 · Primary completion Apr 1, 2022
Drug: ALLOCETRA-OTS · For: Covid19
Sites: Jerusalem, Israel
Enlivex Therapeutics Ltd.Industry
NCT03925857 · 10 participants · Start Jan 27, 2019 · Primary completion Dec 10, 2019
Drug: Allocetra-OTS · For: Organ Dysfunction Syndrome Sepsis
Sites: Jerusalem, Israel
Newest research
PubMed records naming it or its code names, newest first.
- Apoptotic Cell-Based Therapy for the Modification of the Inflammatory Response to Hemorrhagic Shock.
Kenig A, Nachman D, Aliev E, et al. · Mil Med 2024
- Safety of Repeated Administration of Xenogeneic Human Apoptotic State (Allocetra-OTS) in Sprague Dawley Rats.
Ankri C, Hershkovitz O, Hershkovitz L, et al. · Pharmaceutics 2024
- Apoptotic cells for treatment of acute respiratory distress syndrome associated with COVID-19.
van Heerden PV, Abutbul A, Naama A, et al. · Front Immunol 2023
- Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients.
Leyfman Y, Emmanuel N, Menon GP, et al. · J Hematol Oncol 2023
- Apoptotic Cells for Therapeutic Use in Cytokine Storm Associated With Sepsis- A Phase Ib Clinical Trial.
van Heerden PV, Abutbul A, Sviri S, et al. · Front Immunol 2021
- Apoptotic cell therapy for cytokine storm associated with acute severe sepsis.
Karbian N, Abutbul A, El-Amore R, et al. · Cell Death Dis 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.